A Phase I Trial of Lenalidomide and Idelalisib in Recurrent Follicular Lymphoma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 28 Apr 2017
At a glance
- Drugs Idelalisib (Primary) ; Lenalidomide (Primary)
- Indications Follicular lymphoma
- Focus Adverse reactions
- 03 Aug 2015 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2020, as reported by ClinicalTrials.gov.
- 16 Mar 2015 Planned primary completion date changed from 1 Dec 2014 to 1 Dec 2017 as reported by ClinicalTrials.gov record.
- 10 Oct 2014 Status changed from recruiting to active, no longer recruiting according to ClinicalTrials.gov record.